GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Tianjin TEDA Biomedical Engineering Co Ltd (HKSE:08189) » Definitions » Cyclically Adjusted Revenue per Share

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Cyclically Adjusted Revenue per Share : HK$0.00 (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Tianjin TEDA Biomedical Engineering Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tianjin TEDA Biomedical Engineering Co's adjusted revenue per share for the three months ended in Dec. 2024 was HK$0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$0.00 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Tianjin TEDA Biomedical Engineering Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tianjin TEDA Biomedical Engineering Co was -4.00% per year. The lowest was -9.10% per year. And the median was -6.80% per year.

As of today (2025-05-17), Tianjin TEDA Biomedical Engineering Co's current stock price is HK$0.44. Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was HK$0.00. Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tianjin TEDA Biomedical Engineering Co was 0.90. The lowest was 0.15. And the median was 0.37.


Tianjin TEDA Biomedical Engineering Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin TEDA Biomedical Engineering Co Cyclically Adjusted Revenue per Share Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.38 0.34 0.30 -

Tianjin TEDA Biomedical Engineering Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.31 0.30 - -

Competitive Comparison of Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted Revenue per Share

For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted PS Ratio Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted PS Ratio falls into.


;
;

Tianjin TEDA Biomedical Engineering Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tianjin TEDA Biomedical Engineering Co's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/114.8925*114.8925
=0.000

Current CPI (Dec. 2024) = 114.8925.

Tianjin TEDA Biomedical Engineering Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.131 98.900 0.152
201412 0.040 99.000 0.046
201503 0.095 99.900 0.109
201506 0.104 99.500 0.120
201509 0.138 100.500 0.158
201512 0.060 100.600 0.069
201603 0.066 102.200 0.074
201606 0.089 101.400 0.101
201609 0.068 102.400 0.076
201612 0.061 102.600 0.068
201703 0.047 103.200 0.052
201706 0.064 103.100 0.071
201709 0.065 104.100 0.072
201712 0.086 104.500 0.095
201803 0.060 105.300 0.065
201806 0.065 104.900 0.071
201809 0.060 106.600 0.065
201812 0.044 106.500 0.047
201903 0.054 107.700 0.058
201906 0.052 107.700 0.055
201909 0.049 109.800 0.051
201912 0.044 111.200 0.045
202003 0.040 112.300 0.041
202006 0.056 110.400 0.058
202009 0.052 111.700 0.053
202012 0.074 111.500 0.076
202103 0.078 112.662 0.080
202106 0.076 111.769 0.078
202109 0.073 112.215 0.075
202112 0.077 113.108 0.078
202203 0.058 114.335 0.058
202206 0.072 114.558 0.072
202209 0.059 115.339 0.059
202212 0.058 115.116 0.058
202303 0.052 115.116 0.052
202306 0.058 114.558 0.058
202309 0.068 115.339 0.068
202312 0.054 114.781 0.054
202406 0.000 114.781 0.000
202412 0.000 114.893 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tianjin TEDA Biomedical Engineering Co was 0.90. The lowest was 0.15. And the median was 0.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tianjin TEDA Biomedical Engineering Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Tianjin TEDA Biomedical Engineering Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin TEDA Biomedical Engineering Co Business Description

Traded in Other Exchanges
N/A
Address
No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd is engaged in the research, development, and commercialization of biological compound fertilizers, providing elderly and health care services. It operates in two segments namely; biological compound fertilizers products, and elderly care and health care services. The company generates a majority of its revenue from the Fertilisers products segment which is engaged in manufacturing and selling biological compound fertiliser products, including active fertiliser, mixture with nitrogen, phosphorus, and potassium with various formulas, providing warehousing services, and processing and licensing of the fertiliser products. The People's Republic of China is the primary geographical market for the company.
Executives
Long Ortiz 2101 Beneficial owner

Tianjin TEDA Biomedical Engineering Co Headlines

No Headlines